Abstract
About 60% of RA patients don't achieve good response with biological disease-modifying anti-rheumatic drugs bDMARD treatment (including TNF inhibitors, TNFi's). Previously, a link between TNFα and interleukin (IL)-32 was reported in RA. However, the exact mechanism linking IL-32 to response to treatment as not been studied yet. Therefore, we explored the influence of a promoter single nucleotide polymorphism (SNP) rs4786370 in IL-32 on clinical responsiveness to TNFi's in RA patients, potentially serving as new biomarker in RA. Expression of pro-inflammatory cytokines by peripheral mononuclear cells (PBMCs) from RA patients and healthy individuals were studied. Moreover, "ex vivo response" and clinical response to anti-TNFα therapy (etanercept, adalimumab) were measured and stratified for the IL-32 SNP. Higher IL-32 protein production was observed in RA patients. Additionally, patients bearing the CC genotype showed higher IL-32 protein and cytokine expression. DAS28 was independent of the promoter SNP, however, the "ex vivo" cytokine response was not. IL-32 mRNA and protein production was higher in RA patients, with a trend towards higher concentrations in patients bearing the CC genotype. Furthermore, genotype dependent IL-1 ...Continue Reading
References
May 3, 1990·The New England Journal of Medicine·E D Harris
Jul 29, 1989·Lancet·F M BrennanM Feldmann
Jan 1, 1996·Annual Review of Immunology·M FeldmannR N Maini
May 16, 2003·Nature·Gary S Firestein
May 22, 2003·Annals of the Rheumatic Diseases·L PadyukovJ Bratt
Jan 25, 2005·Immunity·Soo-Hyun KimCharles A Dinarello
Feb 24, 2006·Proceedings of the National Academy of Sciences of the United States of America·Leo A B JoostenWim B van den Berg
May 26, 2007·Nature Reviews. Immunology·Iain B McInnes, Georg Schett
Aug 4, 2007·Annals of the Rheumatic Diseases·C Miceli-RichardX Mariette
Apr 18, 2008·Current Atherosclerosis Reports·Saurabh S Dhawan, Arshed A Quyyumi
Oct 8, 2008·Rheumatology·P HarrisonB P Wordsworth
Nov 5, 2008·The Journal of Clinical Investigation·Fionula M Brennan, Iain B McInnes
Jun 23, 2009·European Cytokine Network·Calin PopaMihai G Netea
Jul 25, 2009·American Journal of Respiratory and Critical Care Medicine·Carlo Sorrentino, Emma Di Carlo
Oct 3, 2009·Nature Reviews. Rheumatology·Peter C Taylor, Marc Feldmann
Nov 3, 2009·Cytokine·Jaewoo HongSoohyun Kim
Jan 9, 2010·Annals of the Rheumatic Diseases·S E Gabriel
May 18, 2010·Annals of the Rheumatic Diseases·Bas HeinhuisWim B van den Berg
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Bas HeinhuisLeo A B Joosten
May 19, 2012·Rheumatology·Ken KayakabeYoshihisa Nojima
Nov 21, 2013·Pharmacogenetics and Genomics·Cristina L Dávila-FajardoJavier Martín
Feb 14, 2014·Mediators of Inflammation·Claire I Daïen, Jacques Morel
Aug 27, 2014·Immunology·Dagen LiJu Cao
Nov 10, 2014·Immunologic Research·Carlo SelmiCarlo A Sciré
Feb 18, 2016·Clinica Chimica Acta; International Journal of Clinical Chemistry·Somaiya MateenSwaleha Zubair
Jan 31, 2017·Scientific Reports·Michelle S M A DamenCalin D Popa
Feb 23, 2017·Pharmacology & Therapeutics·Jin Tae HongMi Hee Park
Citations
Jun 1, 2020·Journal of Molecular Neuroscience : MN·Chao LiuYupeng Wang
Feb 10, 2021·Cells·Krzysztof BonekMarzena Ciechomska
Jun 18, 2021·Journal of Medical Virology·Shuo ZhengXiaoping Huang
Aug 5, 2021·Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy·Fatemeh MazlumYousef Bakhshizadeh Ghashti
Nov 21, 2021·Journal of Clinical Laboratory Analysis·Susu JinMinghua Jiang